Treatment of Aspergillus sydowii Infections

Primary Treatment Options

The American College of Physicians recommends voriconazole as the first-line treatment for Aspergillus sydowii infections due to its superior efficacy and survival outcomes compared to other antifungal agents, with a loading dose of 6 mg/kg IV every 12 hours for 1 day, followed by a maintenance dose of 4 mg/kg IV every 12 hours or 200 mg oral twice daily 1, 2
Therapeutic drug monitoring should be considered for voriconazole to ensure adequate serum levels, particularly in cases of treatment failure 1

Liposomal amphotericin B (L-AMB) at 3-5 mg/kg/day IV can be considered as alternative primary therapy in patients who cannot tolerate voriconazole, as recommended by the Infectious Diseases Society of America 1, 3
Itraconazole (200 mg IV every 12 hours for 2 days, then 200 mg daily IV or 200 mg PO twice daily) can be used as an alternative therapy, according to the Clinical Infectious Diseases guidelines 2, 4

For patients who fail primary therapy or cannot tolerate initial treatment, the Infectious Diseases Society of America recommends lipid formulations of amphotericin B (LFAB) 1, 5
Caspofungin (70 mg loading dose on day 1, followed by 50 mg daily IV) can be considered as a salvage therapy option, as suggested by the Clinical Infectious Diseases guidelines 2, 3

Treatment should continue for a minimum of 6-12 weeks, as recommended by the American College of Physicians 1
Therapy should be continued until resolution or stabilization of all clinical and radiographic manifestations, according to the Clinical Infectious Diseases guidelines 2

The site of infection (pulmonary, sinus, CNS, etc.) may influence treatment approach and duration, as noted by the Clinical Infectious Diseases guidelines 2, 4
For CNS aspergillosis, voriconazole is particularly recommended due to its ability to penetrate the blood-brain barrier, as suggested by the Clinical Infectious Diseases guidelines 4

Regular clinical and radiographic assessments should be performed to evaluate treatment response, as recommended by the American College of Physicians 1

Amphotericin B deoxycholate is associated with significant nephrotoxicity and infusion-related adverse events and should be avoided when other options are available, as noted by the Clinical Infectious Diseases guidelines 5
Therapeutic drug monitoring is essential for voriconazole due to its variable pharmacokinetics and narrow therapeutic window, as recommended by the American College of Physicians 1
Some Aspergillus species (like A. terreus) may be resistant to amphotericin B, necessitating azole therapy, as suggested by the American College of Physicians 1